Pooled analysis of three phase 1 and 2 clinical trials published online ahead of print in the journal Lancet Oncology show that the drug entrectinib is effective and well-tolerated against advanced ROS1 and NTRK fusion-positive non-small cell lung cancers (NSCLC). Results of the trials STARTRK-1 (NCT02097810), STARTRK-2 (NCT02568267), and ALKA, show 77 percent response rate to entrectinib in 53 patients with ROS1+ NSCLC, with a median progression-free survival of 19 months and a median duration of response of 24.6 months. In 54 patients with NTRK+ NSCLC, 57 percent responded to entrectinib, with a median progression-free survival of 11.2 months and a median duration of response of 10.4 months. Based on the early promise of these trials, in August 2019 the U.S. Food and Drug Administration granted entrectinib accelerated approval for the treatment of metastatic ROS1+ NSCLC and for advanced tumors across cancer types defined by NTRK fusion. The current journal articles update these findings that led to approval.
Lancet Oncology: Entrectinib effectiv... - Lung Conditions C...
Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases.
Written by
2greys
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
That's amazing 👍
Not what you're looking for?
You may also like...
Looking for guidance
diagnosed with NSCLC stage 4 lung cancer and in the last six month with progression of brain met.
Organising pneumonia - how soon do the steroids kick in?
the 2nd CT scan as a cancerous deposit on my rib. Looks like my breast cancer has come back. I see
